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ABSTRACT The M2 proton channel plays a vital role in the life cycle of the inﬂuenza A virus. His
37, the key residue in the M2
transmembrane domain (M2-TMD), plays a central role in the proton conductance mechanism. The anti-inﬂuenza drug, aman-
tadine, inhibits the channel activity through binding to the pore of the M2 channel. The nuclear spin relaxation data and polari-
zation inversion spin exchange at the magic angle spectra show that both the polypeptide backbone and His37 side chain are
more constrained in the presence of amantadine. Using 15N cross polarization magic-angle spinning NMR spectroscopy, the
protonation of His37 of M2-TMD in lipid bilayers was monitored in the absence and presence of amantadine as a function of pH.
Binding amantadine lowers the His37 pKa values by approximately three orders of magnitude compared with the ﬁrst pKa of
histidine in amantadine-free M2-TMD. Amantadine’s inﬂuence on the His
37 chemical properties suggests a novel mechanism by
which amantadine may inhibit proton conductance.
INTRODUCTION
In binding amantadine to the M2 protein transmembrane do-
main of inﬂuenza A virus several signiﬁcant effects on the
structure, dynamics, and chemical properties of this proton
channel are observed (1–5). Here, studies in planar lipid bi-
layers above the gel-to-liquid-crystalline phase transition and
in liposomes below this phase transition temperature were per-
formed using solid-state NMR. While the structural change
in the polypeptide backbone as viewed by solid-state NMR
has recently been reported (6), here the focus is on the change
in dynamics and in the chemical properties of the histidine
tetrad formed by His37 of this tetrameric protein.
The M2 protein from inﬂuenza A virus is a pH-modulated
proton channel that is essential for viral replication (7,8). These
viruses enter cells through receptor-mediated endocytosis
and are encapsulated by endosomes having a low pH. The
M2 proton channels are activated by low pH and acidify the
viral interior leading to the disruption of the interaction be-
tween the viral matrix proteins and ribonucleoproteins, a pre-
requisite process for the release of viral RNA into the cell. In
addition to its function in the uncoating process, the M2 chan-
nels also equilibrate the pH between the acidic trans-Golgi
network and the cytoplasm. Amantadine (1-adamantanamine
hydrochloride) is a speciﬁc anti-inﬂuenza A drug that inhib-
its viral replication, primarily by binding to the M2 protein
and thereby preventing proton conductance (9–11). Without
the acidiﬁcation of the viral interior, the uncoating process
for the inﬂuenza A virus fails to occur (12,13). Moreover, the
hemagglutinins in the trans-Golgi network are forced to
adopt a low-pH conformation due to the blocked M2 chan-
nels (14,15).
Although amantadine is effective as a preventative prophy-
laxis and as a treatment of the inﬂuenza A viral infections, its
clinical use as an anti-inﬂuenza drug is limited due to its cen-
tral nervous system side effects (16). Rimantadine (a-methyl-
1-adamantane-methanamine), an amantadine analog, has been
considered a better anti-viral drug because of its enhanced
activity and fewer side effects (17,18). However, in the past
year, the prevalent Inﬂuenza A (H3N2) strain was the S31N
mutant that is amantadine-resistant (19). It is generally be-
lieved that the rigid amantadine molecule sterically blocks
the M2 transmembrane pore, thereby preventing proton con-
duction. However, this mechanism remains controversial as
it is inconsistent with some of the electrophysiological obser-
vations for the M2 channels (20) and may also be inconsis-
tent with results obtained from amantadine-resistant mutants
(4). While the mechanism of amantadine binding to the M2
channel is unclear, many amantadine analogs have been syn-
thesized to test their antiviral activities (21–23).
The M2 protein has 96 amino-acid residues with a single
19-residue transmembrane domain (24,25). The functional
structure of the M2 channel is minimally tetrameric (26–28).
Electrophysiological studies demonstrate thatM2 protein selec-
tively conducts protons through a variety of membrane sys-
tems, such as oocytes of Xenopus laevis, mammalian cells,
and planar lipid bilayers (29–31). Signiﬁcant suppression of
proton conduction by amantadine or rimantadine in these sys-
tems is well documented.
The transmembrane domain of M2 (M2-TMD) also forms
a proton selective channel in lipid bilayers that is sensitive to
amantadine (32). Analytical ultracentrifugation experiments
show that amantadine stabilizes the formation of the M2-TMD
tetramer (1). Structural information onM2-TMD has been ob-
tained by cysteine-mutagenesis (33), molecular dynamics (34),
UV resonanceRaman spectroscopy (2), Fourier transform infra-
red spectroscopy (35), solid-state NMR spectroscopy (36–38),
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and electron spin resonance (39). Uniquely, solid-state NMR
has led to a high-resolution backbone structure of the mono-
mer while in a tetramer conﬁguration (PDB ID: 1MP6, (36)).
The addition of a precise distance restraint between helices
has resulted in a structure of the tetrameric transmembrane do-
main (PDB ID: 1NYJ; (38)). Interestingly other spectroscopic
data suggests somewhat different tilt angles for the helices
depending on the membrane mimetic environment (39). The
M2-TMD structure built on the basis of solid-state NMR ori-
entational and distance restraints indicates a channel pore
lined by polar residues (Ser31, His37, and Trp41) that can ac-
commodate an amantadine molecule (38). Nevertheless, spec-
troscopic evidence from ﬂuorescence (1) and circular dichroism
(3) indicates that some structural rearrangement takes place
upon amantadine binding. The M2-TMD/amantadine model
proposed by Gandhi et al. (40) reﬂects some insights for
this structural alteration and suggests a potential hydrogen-
bonding interaction between the nonprotonated His37 Nd1
and the amantadine amino group. Recently, the backbone
structure of the amantadine-bound state has been determined
(PDB ID: 2H95; (6)) showing a kinked helical structure, but
the position of amantadine within the structure was not
deﬁned.
Here, by using 15N cross-polarization magic-angle spin-
ning (CPMAS) NMR spectroscopy, we titrated the M2-TMD
histidine in the presence and absence of amantadine as a func-
tion of pH. The effect of amantadine binding on the His37
side-chain motion was studied by comparing the cross polar-
ization efﬁciency for the His37 15Nd1 signal with and without
amantadine. The conformational and dynamic changes in the
M2-TMD backbone upon amantadine binding were also mon-
itored by polarization inversion spin exchange at the magic
angle (PISEMA) experiments (41,42).
MATERIALS AND METHODS
Peptide synthesis and sample preparation
15Nd1 histidine and 15Ne2 histidine were purchased from Cambridge Isotope
Laboratories (Cambridge, MA) and chemically protected by trityl and
9-ﬂuorenylmethoxycarbonyl (Fmoc) groups following literature procedures
(43,44). The total yield of 9-ﬂuorenylmethoxycarbonyl -His-(trityl)-OH
was 73–81%. The M2-TMD peptide, NH2-Ser
22-Ser-Asp-Pro-Leu-Val-Val-
Ala-Ala30-Ser-Ile-Ile-Gly-Ile-Leu-(15Nd1 or 15Ne2)His37-Leu-Ile-Leu40-Trp-
Ile-Leu-Asp-Arg-Leu46-COOH was chemically synthesized by solid-phase
synthesis on an Applied Biosystems (Foster City, CA) model No. 430A
synthesizer. The peptides were puriﬁed and characterized as described pre-
viously (37).
15N His37 labeled M2-TM domain was incorporated into liposomes through
the assistance of a detergent, 1-O-octyl-b-D-glucopyranoside (OG) (45).
First 10 mg M2-TMD peptide, 40 mg 1,2-dimyristoyl-sn-3-phosphocholine
(DMPC), 10 mg 1,2-dimyristoyl-sn-glucero-3-[phospho-rac-(1-glycerol)]
(DMPG), and 320 mg OG were codissolved in 20 ml 2,2,2-triﬂuoroethanol
(TFE) and chloroform (v/v: 4/1). An OG/lipid ratio of 15:1 allows for the
preparation of a highly homogeneous sample of vesicles after OG is dialyzed
out later in this procedure (46). The organic solvent was evaporated from a
rotary ﬂask and then the mixture was placed under high vacuum for at least
6 h to remove residual organic solvent. Fifteen milliliters of 10 mM citrate-
borate-phosphate (CBP) buffer of a speciﬁc pH with 1 mM ethylenedia-
minetetraacetic acid was added to the dried mixture and a clear solution was
prepared after the ﬂask was shaken in a bath for;20 min at 37C (above the
gel-to-liquid-crystalline phase transition temperature of DMPC (;23C)
(47). This solution was then transferred into a dialysis bag with a 3 kDa
cutoff and dialyzed at 4C against the buffer, which was changed at least ﬁve
times in ﬁve days to ensure virtually complete removal of the detergent. For
an M2-TMD sample with 10 mM amantadine, 46.9 mg (250 mmol) aman-
tadine hydrochloride (Thermo Fisher Scientiﬁc, Waltham, MA) in 5 ml CBP
buffer was added to an M2-TMD loaded vesicle suspension (20 ml). The
suspension was incubated at room temperature overnight and pelleted in 2.5
h by ultracentrifugation at 196,000 g. The pH value of the pellet was implied
from a measurement of the supernatant. Finally, the M2-TMD in DMPC/
DMPG liposomes with or without amantadine was packed into a 7 mm
Bruker (Madison, WI) zirconia magic-angle rotor with a sealing cap ready
for CPMAS NMR experiments.
Oriented samples of the 15N-(L26, L36, L38, L40, L43) and 15Ne2 His
labeled peptide in hydrated DMPC bilayers were prepared by ﬁrst codis-
solving M2-TMD (20 mg) and DMPC (75 mg) in 10 ml TFE. TFE was
removed by rotary evaporation and dried further under high vacuum. Fifteen
milliliters of 2 mM CBP buffer (;37C, pH 8.8) with 1 mM ethylene-
diaminetetraacetic acid was added to the dried mixture and shaken at 37C.
This lipid suspension was bath-sonicated for 10 min intermittently. The soni-
cated suspension was loaded into a 1 kDa cutoff dialysis bag. The dialysis
bag was placed in 1 L of 2mM CBP buffer overnight to adjust the pH of the
M2-TMD/DMPC liposomes. For the samples with amantadine, the outside
buffer contained 10 mM amantadine. The liposomes were passed through a
2-mm ﬁlter and pelleted by ultracentrifugation at 196,000 g. As above, the
pH of the supernatant was measured with an accuracy of 60.05. The pellet
was agitated at 37C for 1 h until ﬂuid. This viscous ﬂuid was spread onto 50
glass slides (5.7 mm3 12.0 mm) (Marienfeld Glassware, BadMargentheim,
Germany) and dried in a constant humidity (70–75% relative humidity)
chamber using an N2 atmosphere. The dehydrated slides were rehydrated
with 1.5 ml, 2 mMCBP buffer per slide followed by stacking the slides into a
glass tube. The sample was incubated at 43C for 24 h in 96% humidity
(saturated K2SO4) chamber. Finally, the glass tube was sealed at both ends
with epoxy and two glass caps.
Solid-state NMR experiments
All CPMAS NMR experiments were conducted on a Bruker DMX-300
NMR spectrometer at 277 K using a spinning rate of 3 kHz. Two milli-
seconds cross-polarization contact time and 5 s recycle delay were used
throughout the variable-pH NMR experiments. One-hundred Hertz expo-
nential line broadening was applied to the free induction decay before Fou-
rier transform. Static 31P NMR experiments on oriented samples at 303 K
were also performed using the Bruker DMX-300 NMR spectrometer with an
NHMFL 31P/1H double resonance probe. The two-dimensional PISEMA
experiments were performed at 303 K on a 400 MHz spectrometer using an
NHMFL 15N/1H double resonance probe. Typically, a 6 s delay was applied
before the 1H 90 pulse (52.1 kHz ﬁeld). This RF ﬁeld was also applied
during the 1H-15N cross polarization (800 ms) and 1H continuous wave de-
coupling, while an RF ﬁeld of 63.7 kHz was used during the Lee-Goldberg
spin exchange at the magic angle. Proton carrier frequencies were carefully
adjusted to minimize the offset effect (48,49). Thirty-two t1 increments with
512 or 1024 transients were recorded for the two-dimensional PISEMA
spectra. 15N chemical shift of a saturated 15NH4NO3 was deﬁned as 0 ppm
for all 15N spectra.
The 1H spin-lattice relaxation time in the rotating frame (TH1r) was mea-
sured using a standard pulse sequence described previously (50,51). In short,
after a 90 pulse on the 1H channel, the 1H magnetization was spin-locked
for a period of time tSL before making CP contact with the
15N spins. With a
ﬁxed CP contact time (2 ms), the polarized 15N signals detected with 1H
decoupling monitored the 1H magnetization in the spin-lock ﬁeld as a func-
tion of tSL, thus allowing one to measure T
H
1r indirectly. For variable-contact
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CP experiments, CP occurs right after the ﬁrst 90 1H pulse and the contact
time was varied from 100 ms to 10 ms (50).
RESULTS AND DISCUSSION
Amantadine binding effect on M2-TMD resonances
Chemical structures and the chemical shift resonances of
histidine side chains in M2-TMD depend upon the local en-
vironment. In addition, neutral histidines may also undergo
tautomerization. Fig. 1 illustrates the resonance assignment
of histidines for the different chemical states in the M2-TMD
channel (52). Generally, 15Ne2/d1-1H of positively charged his-
tidines contributes to signals in the range of 153–156 ppm
(53), while the neutral histidine side chains give rise to chem-
ical shifts between 144 and 147 ppm. Neutral 15Nd1-1H loses
a proton due to tautomerization, resulting in 15Nd1 signals
resonating at 230 ppm. HisH1-His hydrogen-bonding shifts
15Ne2/d1-1H to a lower ﬁeld, while the nonprotonated nitro-
gen shifts to a higher ﬁeld (60). For M2-TMD in the absence
of amantadine, the protonated nitrogen was observed between
162 and 167 ppm (52).
Fig. 2 A displays the CPMAS NMR spectra of 15Ne2
labeled His37 M2-TMD with and without amantadine at pH
8.8. The 15N chemical shifts of 144 ppm indicate that his-
tidines are neutral in both cases at this pH. The striking dif-
ference in these spectra is the improvement in linewidth upon
binding amantadine, suggesting that the amplitude of low
frequencymotions has been dramatically reduced or that con-
formational heterogeneity has been greatly reduced upon
amantadine binding. Shown in Fig. 2 B is PISEMA data from
the 15N-Leucine labeled M2-TMD prepared in an analogous
fashion to the 15N His37 samples. Once again, a dramatic im-
provement in linewidth is observed upon binding amanta-
dine. Consequently, if there is a reduction in low frequency
motion it pertains to both the histidine side chain and the
backbone throughout the TM helix. Furthermore, since the
FIGURE 1 Chemical shift assignments associated with the chemical states
of histidines in M2-TMD. In the presence of amantadine, His -HisH
1 dimeri-
zation does not occur. (N.O., not observed.)
FIGURE 2 15N solid-state NMR spectra of M2-TMD in lipid bilayer
environments with (bottom) and without (top) amantadine bound. (A)
CPMAS NMR spectra of His37 (15Nd1) M2-TMD in DMPC/DMPG (4:1
molar ratio) at pH 8.8. Spectra were obtained at 277 K with a spinning rate
of 3 kHz. (B) PISEMA spectra of ﬁve-site 15N leucine labeled M2-TMD at
pH 9.0 in DMPC bilayers at 298 K.
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PISEMA resonances directly and sensitively reﬂect the orien-
tation of these backbone sites with respect to the labora-
tory frame, the well-resolved resonances in the M2-TMD/
amantadine spectrum deﬁne a unique structure with little
orientational mosaic spread. Either local (peptide plane) or
global (helix) disorder would broaden the resonances in the
PISEMA spectrum. Such a situation is observed when
amantadine is absent, but not in its presence. In addition, the
PISEMA spectrum of 15Ne2-His37 M2-TMD in the presence
of amantadine at pH 9 shows a well-deﬁned splitting (Fig. 3)
consistent with a unique conformation having little disorder
(54). As indicated from thermal stability studies of M2-TMD
mutants (5), the dynamics or conformational heterogeneity
in the absence of amantadine when the channel is functional
appears to require structural ﬂexibility to be sensitive to the
chemical stimulus (e.g., H1).
Slow dynamics of the His37 side chain
In the CPMAS experiments, it is not possible to quantita-
tively compare the intensities of the protonated and non-
protonated 15N resonance intensities directly. For the case
where TH1r is approximately equal to the CP buildup time TNH,
Fu and co-workers developed a Lee-Goldburg frequency-
modulated CP approach to improve the TH1r and CP buildup
rate (50). Under long CP contact conditions, a relatively ac-
curate estimate of the ratio between nonprotonated and pro-
tonated histidine resonances is achieved by integrating the
signals in the Lee-Goldburg frequency-modulated CP spec-
trum. For membrane protein samples in hydrated lipid bi-
layers, TNH is often similar to or even longer than T
H
1r. In this
case, it is inappropriate to apply the above methods to deﬁne
the relative amount of each component in the CPMAS NMR
spectrum and we have resorted here to analyzing the cross
polarization kinetics followed by the development of a cor-
rection factor to calculate the relative number of protonated
and nonprotonated sites. In addition to the measurements of
TH1r and TNH, the intensities of the spinning side bands for the
nonprotonated state must also be included (50).
The mobility of the His37 side chain can be assessed by
measuring the relaxation parameters controlling the 15N CP
process. Here, we make the reasonable assumption that TNH
is much shorter than the 15N spin-lattice relaxation time in
the rotating frame (TN1r, (55)). Then the signal intensity of a
given species,M(tCP), can be characterized by the equation (56)
MðtCPÞ ¼ M0 1
TNH
TH1r
 !1
exp tCP
TH1r
 !
 exp tCP
TNH
 " #
;
(1)
where tCP is the CP contact time and M0 is a constant that is
proportional to the number of spins. Using a standard CP ex-
periment (51), TH1r can be measured experimentally by ﬁtting
the signal intensities as a function of spin-lock time before
CP tSL with
MðtSLÞ ¼ M0exp 
tSL
T
H
1r
 !
: (2)
Using the 15Nd1-His37 M2-TMD sample at pH 8.8, data for
both the 147 ppm and 230 ppm resonances were collected
simultaneously. The values of TH1r, M0, and TNH in the ab-
sence and presence of amantadine are listed in Table 1.
The inverse of the CP buildup time of the dilute spin
15N signal cross-polarized from the abundant spin 1H, 1/TNH,
more often called the CP rate constant, is predominantly con-
trolled by the NH dipolar coupling. Roughly, the CP rate is
proportional to the square of the dipolar coupling between
1H and 15N (57,58). This explains why the signal buildup for
the protonated 15Nd1 (147 ppm) resonance is approximately
two orders-of-magnitude faster than for the nonprotonated
resonance (230 ppm). Consequently, the observed intensities
for protonated and nonprotonated sites at a single cross-
polarization time cannot be compared directly without taking
the cross-polarization kinetics into account.
Molecular motions can average and hence reduce dipolar
interactions and therefore TNH can provide a qualitative de-
scription of the motional difference in the presence and ab-
sence of amantadine. Here we assume that the magic angle
spinning rate does not affect the TNH values (59) and that the
Hartmann-Hahn condition was well matched. In the presence
of amantadine, TNH is approximately half that in its absence.
In other words, the 15N-1H dipolar interaction in the absence
of amantadine is 22% smaller due to the motional averaging
in the His37 side chain. For amantadine-bound M2-TMD,
both the backbone (Fig. 2 B) and side-chain (Fig. 3)
PISEMA data suggest less conformational heterogeneity
and/or reduced motional amplitude. Coupled with the TNH
results, it is clear that the amantadine-bound state is more
rigid and conformationally more homogeneous. In addition,
the PISEMA data for amantadine-bound M2-TMD has been
used to characterize an altered backbone structure involving
a kinked a-helical structure (6).
FIGURE 3 15N PISEMA spectra of 15Ne2 His37 labeled M2-TMD in
aligned DMPC planar bilayers with amantadine bound at pH 9.0. The
PISEMA spectra were acquired on a 400 MHz spectrometer at 298 K.
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His37 tautomerization
On the basis of the values of M0 for the 147 and 230 ppm res-
onances, the nonprotonated d1 tautomer was found to be at
least three times more favorable than the protonated d1 tau-
tomer (Table 1). Amantadine does not appear to change the
population of the two tautomers. In solution, free histidine fa-
vors the nonprotonated d1 tautomer with an ;4:1 ratio (60).
It is intriguing that the neutral histidines in the M2-TMD
channel behave similarly as they do in the bulk solution.
This ratio suggests that one out of four histidines is in the
d1-protonated tautomeric state and hence is unlikely to be
adjacent to another d1-protonated His37 residue.
Even without charged residues, the presence of both tau-
tomeric forms breaks the fourfold symmetry of the structure.
The observation of distinct nonprotonated (230 ppm) and pro-
tonated (147 ppm) sites clearly demonstrates that the His37
residues undergo side-chain tautomerization at a rate slower
than 2.5 kHz based on the separation of these two resonances
in Hz for a sample in a 7 Tesla magnet (30 Hz/ppm 3 83
ppm). At the same time, one might expect structural differ-
ences based on the tautomer heterogeneity that would be
observed in the PISEMA spectra. We can expect a proton-
ated 15Ne2 imidazole to be located in each of the three posi-
tions in the tetrad with a nonprotonated residue in the other
site. Each of these imidazoles has a different local environ-
ment based on the protonation of the imidazoles on either
side and each conﬁguration could result in a different orien-
tation for the 15Ne2 imidazole. The observation of a unique
15N-1H dipolar coupling and 15N chemical shift for both the
15Ne2 sites (Fig. 3) and the polypeptide backbone (Fig. 2 B)
suggest that the structural difference causes ,2 kHz change
in the dipolar splitting; otherwise, multiple splittings would
be observed. Such a small change in dipolar splitting trans-
lates to very small changes in either the backbone amide
planes or the imidazole ring orientations.
Low proton afﬁnity of His37 with amantadine
Fig. 4 shows the pH titration for the d1 site in the presence
and absence of amantadine. Resonances at 230 and 147 ppm
arise from the nonprotonated and protonated (neutral) 15Nd1
sites, respectively (54). In addition to the neutral tautomeric
states, two additional resonances are observed. The reso-
nances at 156 ppm represent the biprotonated charged state
and the broad resonance at 167 ppm (only in the absence of
amantadine) reﬂects the formation of the His-HisH1 dimer
(52,61). In the absence of amantadine the observed reso-
nance intensities (corrected for cross-polarization kinetics
and spinning side-band intensities) have been interpreted to
yield a set of pKa values for this histidine tetrad: 8.2, 8.2, 6.3,
and,5.0 (Fig. 5). As discussed previously (52) this titration
results in a couple of unique conclusions. The ﬁrst two his-
tidines to titrate appear to titrate with cooperative proton
binding and at very high pH compared to the normal pKa of
histidine. Secondly, the binding of these protons appear to
form His-HisH1 dimers that distribute the charge through
the formation of low-barrier hydrogen bonds.
TABLE 1 Summary of NMR relaxation parameters and relative population of 15Nd1 230 ppm and 147 ppm signals
TH1r (ms)* TNH (ms)* M0 Relative amount
y
Peak position
(ppm)
With
amantadine
No
amantadinez
With
amantadine
No
amantadinez
With
amantadine
No
amantadinez
With
amantadine
No
amantadinez
230 ($N) 4.2 6 0.9 5.2 6 1.6 6900 6 590 11400 6 420 9.9 6 0.3 286 6 9 3.3 3.5
147 (.N-H) 4.8 6 1.6 5.1 6 0.9 65 6 30 170 6 30 3.0 6 0.3 81 6 3 1 1
*The errors are obtained from the curve ﬁtting to Eqs. 1 and 2.
yThe relative amount is calculated from the ratio of M0 between different species.
zThe amantadine-free data were adopted from Hu (54).
FIGURE 4 CPMASNMRspectra ofHis37 (15Nd1)M2-TMDwith andwith-
out amantadine at different pH values. Spectra were obtained on a Bruker
DMX-300 NMR spectrometer at 277 K with a spinning rate of 3 kHz.
Signals at ;100 ppm are from the natural abundance amides from the
M2-TMD backbone. Spinning side bands are marked with asterisks.
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In the presence of amantadine, there are two striking
changes in the pH titration. First, the nonprotonated d1 res-
onance, indicative of the uncharged monomeric state, is
present even at pH 5, while in the absence of amantadine this
resonance disappeared between pH 7.0 and 8.0. Conse-
quently, the ﬁrst pKa values for this histidine tetrad have
shifted to much lower pH values in the presence of aman-
tadine. Secondly, there is little or no evidence for a resonance
at 167 ppm, suggesting that the His-HisH1 dimer does not
form in the presence of amantadine. As shown in Fig. 5, the
pKa values appear to be in the vicinity of 5.4. The proton-
ation at this pH does not appear to be associated with the
dissociation of amantadine from M2-TMD, based on the nar-
row linewidths observed even at very low pH in the presence
of amantadine. Neither is it very reasonable to propose uni-
form pKa values for each of the four His
37 residues, unless
the tetrameric structure is not stable below this pH. The
tetramerization studies for M2-TMD suggest that the tetra-
mer is not very stable below pH 6 in micelles (1); however, it
is anticipated to be much more stable in lipid bilayers, as
suggested by the conductance studies of M2-TMD (32,52).
In addition, it has been shown that binding amantadine to
M2-TMD (1) stabilizes the tetrameric complex. Consequently,
we do not anticipate that the tetramer is dissociating at this
pH. However, it is likely that there is a structural change that
is permitting multiple protonations of the His37 residues at
this low pH. Unfortunately, it is difﬁcult to obtain structural
data at this pH due to conformational heterogeneity (54).
The lack of His-HisH1 dimer suggests that water is in
an appropriate orientation to access the imidazole nitrogens
and to compete for these hydrogen-bonding sites, thereby pre-
venting the formation of low-barrier His-HisH1 hydrogen
bonds. This appears to be in conﬂict with the Trp41 ﬂuores-
cence emission results reported by Salom et al. (1), in which
they suggest that, upon binding amantadine, the environment
for Trp41 becomes more hydrophobic. However, other expla-
nations for the failure to form His-HisH1 dimers are also
possible; for instance, the cooperativity in proton binding in
the absence of amantadine suggests that a structural change
is induced by the formation of the ﬁrst His-HisH1 dimer and
that the resultant tense state is relieved when a second proton
is bound, forming a second and symmetric His-HisH1 dimer.
The observed titration in the presence of amantadine may
then be consistent with the formation of individual bipro-
tonated histidines in the M2-TMD.
The inﬂuence of amantadine on the chemical properties of
this histidine tetrad observed here suggests the possibility of
a novel mechanism for how amantadine may inhibit proton
conductance. It has long been assumed that amantadine ste-
rically blocks the pore formed by the M2 protein four-helix
bundle. However, Arkin and co-workers (4), in studying aman-
tadine resistant mutants by surface plasmon resonance, has
observed that a subset of these mutants still bind amantadine
and yet proton conductance is not blocked. While it is pos-
sible to make an argument on steric grounds to explain this
result, it is also possible to speculate that the inﬂuence of
amantadine on the chemical properties of the histidine tetrad
could be modiﬁed in these mutants and hence form a distinct
functional mechanism.
In conclusion, the structure of the transmembrane domain
of M2 at high pH and in the absence of amantadine is more
dynamic and structurally heterogeneous compared with the
structure when amantadine is bound. It is likely that the dy-
namics and structural plasticity are essential for the functional
complexity of channel opening, gating, and proton conduc-
tion, both for the isolated transmembrane domain and for the
full-length protein. There is growing evidence in the liter-
ature that there is a large number of membrane proteins for
which the transmembrane domain and water-soluble domain,
at least in part, function separately. For instance, the CorA
Mg21 transporter structure was recently solved by crystal-
lizing the water-soluble domain and then using that structure
to solve the full-length protein structure (62). Many prop-
erties of the M2 transmembrane domain and the full-length
protein appear to be, at least, qualitatively the same, such as
tetramerization, proton conductance, and amantadine bind-
ing. Here, amantadine appears to interfere with the unique
chemistry of the histidine tetrad in the transmembrane do-
main; we would anticipate the same in the full-length pro-
tein. Not only are the pKa values drastically altered, but the
formation of low-barrier hydrogen bonds appears to be
impossible in the presence of amantadine—suggesting that
the mechanism by which amantadine prevents proton con-
ductance may not be steric hindrance, but instead a mech-
anism that interferes with the histidine facilitation.
FIGURE 5 Curves for Nproton versus pH in the presence (dashed line) and
absence (solid line) of 10 mM amantadine. Nproton is the number of released
protons from the His37 tetrad at a given pH value. At each pH value, Nproton
was calculated on the basis of the ratio of M0 for different histidine species
(54). The Nproton versus pH data in the presence of amantadine were ﬁtted
assuming that there is a single kind of titratable histidine in the channel,
while for the amantadine-free M2-TMD multiple titration states must be
considered and the ﬁtting curve was adopted from Hu et al. (52) for the
purpose of comparison. Both ﬁtting curves were generated using the non-
linear regression ﬁtting program in Origin 6 (Microcal Software, North-
ampton, MA).
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